Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2018

Nov 13, 2018

SELL
$167.73 - $192.74 $10.1 Million - $11.6 Million
-60,000 Closed
0 $0
Q2 2018

Aug 13, 2018

BUY
$145.72 - $169.96 $8.74 Million - $10.2 Million
60,000 New
60,000 $10.2 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Granite Point Capital Management, L.P. Portfolio

Follow Granite Point Capital Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Granite Point Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Granite Point Capital Management, L.P. with notifications on news.